Epigenomics AG / Key word(s): Capital Increase
28.05.2015 11:25
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad Hoc Announcement pursuant to Sec. 15 WpHG (German Securities Trading
Act)
Epigenomics AG Places Maximum Number of New Shares in Capital Increase with
Pre-emptive Rights
Not for distribution in the United States of America
Berlin, Germany, May 28, 2015 - Epigenomics AG, Berlin, Germany (Frankfurt
Prime Standard: ECX; ISIN: DE000A11QW50) announces that the Company will
fully implement the capital increase as announced on May 11, 2015, hereby
raising gross proceeds in the total amount of EUR 4,999,997.44.
Today, the Executive Board of the Company, with the approval of the
Supervisory Board, resolved on the increase of the Company's share capital
in the amount of EUR 976,562.00 by issuing 976,562 new no-par value
registered shares ("Namensstückaktien") representing a notional portion of
the share capital of EUR 1.00 per share from the Company's Authorized
Capital 2014/II. The details of the capital increase were announced on May
11, 2015 via ad-hoc notification.
All of the 976,562 new registered shares that have been offered during the
subscription period from May 13, 2015 until May 27, 2015 were taken up by
existing shareholders of the Company at a subscription price of EUR 5.12
per share. The technical implementation of the capital increase was
conducted by Bankhaus Neelmeyer.
Subject to the registration of the implementation of the capital increase
with the commercial register ("Handelsregister") the admission of the new
shares to the regulated market ("regulierter Markt"), Prime Standard, of
the Frankfurt Stock Exchange is expected on or around June 9, 2015. Trading
in the new shares is expected to begin on June 11, 2015, and delivery of
the new shares to the investors is expected on June 11, 2015.
Epigenomics AG intends to use the net proceeds from the offering to finance
market introductory measures for Epi proColon(R) in the U.S., to strengthen
its manufacturing capabilities as well as to build product inventory and
lastly to finance its current business operations.
- End of Ad hoc -
Disclaimer
This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.
This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States of America. The shares
of Epigenomics AG (the "Shares") have not been registered under the U.S.
Securities Act of 1933, as amended (the "Securities Act"), and may not be
offered or sold in the United States unless registered under the Securities
Act or pursuant to an exemption from such registration. There will be no
public offering of the Shares in the United States and the Shares will not
be registered under the Securities Act.
Contact:
Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
28.05.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
28. May 2015 - 0:00 (CEST)